A chance discovery made in my lab 17 years ago results in the first drug that can help patients with a rare disease.
Advertisement
The Scientist
Most Recent
Researchers are finding new drugs for chronic pain and autoimmune diseases by modifying animal venom-derived molecules that target the nervous and immune systems.
Two experts propose replacing Phase 3 trials with smaller, faster alternatives and post-market surveillance to invigorate the pharmaceutical industry.
Contrary to previous assumptions that macrolide antibiotics completely block the exit tunnel of ribosomes, new evidence shows that some peptides are allowed to pass.
An Oregon teenager spent a summer in a New York biochemistry lab helping to discover a novel molecule that could become the next commercial nonaddictive painkiller.
Despite decades of work, compounds in frog skins have failed to yield new antibiotics. Why?
As the United States edges ever closer to the dreaded fiscal cliff, the pharmaceutical industry approaches a precipice of its own.
Senior Scientist, Millennium Pharmaceuticals: The Takeda Oncology Company Age: 39
After two headline successes, companies rush to develop “smart bomb” cancer drugs.
A new camera system allows researchers to measure multiple cardiac signals at once to understand how they interact to control heart function.
Page 1 of 1
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
